Development and psychometric properties of a new brief scale for subjective personal agency (SPA-5) in people with schizophrenia.
Adult
Community Mental Health Services
/ standards
Cross-Sectional Studies
Factor Analysis, Statistical
Female
Focus Groups
Humans
Interviews as Topic
Male
Middle Aged
Personal Autonomy
Psychometrics
/ instrumentation
Reproducibility of Results
Schizophrenia
/ diagnosis
Schizophrenic Psychology
Social Behavior
Surveys and Questionnaires
/ standards
Assertive community treatment
personal agency
scale development
schizophrenia
Journal
Epidemiology and psychiatric sciences
ISSN: 2045-7979
Titre abrégé: Epidemiol Psychiatr Sci
Pays: England
ID NLM: 101561091
Informations de publication
Date de publication:
10 Apr 2020
10 Apr 2020
Historique:
entrez:
11
4
2020
pubmed:
11
4
2020
medline:
2
6
2020
Statut:
epublish
Résumé
Personal agency is a variable which potentially facilitates personal recovery in people with serious mental illness. This study aimed to develop a new brief measure for subjective personal agency that can be completed by people with serious mental illness. Two focus group interviews were first conducted with 11 people with schizophrenia to understand the fundamental components of subjective personal agency for people with serious mental illness living in the community. One group comprised six people with schizophrenia living in the community, while the other consisted of five people with schizophrenia working as peer-support workers. We then developed scale items through collaboration with people with schizophrenia and qualitative analysis (stage 1). A cross-sectional survey was then conducted to test the psychometric properties of the new scale among service users with schizophrenia in 18 assertive community treatment teams (stage 2). Factor validity was tested via exploratory factor analysis (EFA) and confirmatory factor analysis (CFA). We evaluated convergent validity with the Boston University Empowerment Scale (BUES), divergent validity with the global assessment of functioning (GAF), internal consistency, and test-retest reliability. Seven items were included in the scale at stage 1. In stage 2, 195 participants completed this scale. EFA revealed a one-factor model with five items. CFA indicated good model fit (χ2 statistics [CMIN] = 8.445, df = 5 (CMIN/df = 1.689), p = 0.133, comparative fit index = 0.974, Tucker-Lewis fit index = 0.949, root mean square error of approximation = 0.077 and standardised root mean squared residual = 0.042). The new scale was significantly correlated with total BUES score (r = 0.526, p < 0.001), but not with GAF score. Cronbach's α for internal consistency was 0.79, and intra-class correlation coefficient for test-retest reliability was 0.70. We developed a new, five-item Subjective Personal Agency scale (SPA-5) that can be completed by people with serious mental illness. Further studies are needed to confirm the results outside Japan.
Identifiants
pubmed: 32272978
doi: 10.1017/S2045796020000256
pii: S2045796020000256
pmc: PMC7214545
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e111Références
World Psychiatry. 2012 Oct;11(3):156-60
pubmed: 23024667
Psychiatr Serv. 1997 Aug;48(8):1042-7
pubmed: 9255837
Psychol Med. 2000 Sep;30(5):1131-9
pubmed: 12027049
Br J Psychiatry. 2018 Jan;212(1):42-49
pubmed: 29433611
Brain. 2010 Oct;133(10):3104-12
pubmed: 20685805
Philos Trans R Soc Lond B Biol Sci. 2000 Dec 29;355(1404):1771-88
pubmed: 11205340
Br J Psychiatry Suppl. 2007 Aug;50:s21-8
pubmed: 18019040
Qual Life Res. 2018 Jul;27(7):1893-1902
pubmed: 29675691
Front Psychol. 2017 Sep 12;8:1552
pubmed: 28955273
Br J Psychiatry. 2011 Dec;199(6):445-52
pubmed: 22130746
Int J Ment Health Syst. 2019 Jun 7;13:40
pubmed: 31182972
World Psychiatry. 2012 Oct;11(3):165-6
pubmed: 23024671
Schizophr Bull. 2007 Sep;33(5):1225-37
pubmed: 17204532
Schizophr Bull. 2012 Mar;38(2):304-15
pubmed: 20624752
Br J Psychiatry. 2012 Oct;201(4):262-7
pubmed: 23028084
BMJ. 2018 Sep 10;362:k3798
pubmed: 30201610
Health Expect. 2017 Feb;20(1):11-23
pubmed: 26889874
PLoS One. 2015 May 13;10(5):e0126553
pubmed: 25970618
Trends Cogn Sci. 2000 Jan;4(1):14-21
pubmed: 10637618
Am J Psychiatry. 2007 Mar;164(3):458-66
pubmed: 17329471
Patient. 2012;5(2):79-87
pubmed: 22428752
Psychiatry Clin Neurosci. 2013 Sep;67(6):384-96
pubmed: 23890091
Community Ment Health J. 2018 Aug;54(6):793-804
pubmed: 29188393
Schizophr Bull. 2018 Apr 6;44(3):631-642
pubmed: 29036720
Psychiatr Rehabil J. 2019 Jun;42(2):169-181
pubmed: 30843721
Psychiatry Clin Neurosci. 2007 Dec;61(6):594-601
pubmed: 18081618
Arch Psychiatr Nurs. 2015 Dec;29(6):372-6
pubmed: 26577549
BMC Health Serv Res. 2015 Sep 16;15:388
pubmed: 26376978
Nature. 2018 Oct;562(7725):32-33
pubmed: 30283121
Adm Policy Ment Health. 2018 Jan;45(1):91-102
pubmed: 27709376
Qual Life Res. 2018 May;27(5):1147-1157
pubmed: 29435801
World Psychiatry. 2014 Feb;13(1):24-7
pubmed: 24497239